Clinical Trial Update: Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity [Phase 3]

View source ↗

Summary

Phase 3 trial comparing intravitreal ranibizumab for aggressive versus Type 1 prethreshold retinopathy of prematurity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retina Disease
• Retinopathy of Prematurity

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Zagazig University | Conditions: Retina Disease, Retinopathy of Prematurity | Phase 3 | Status: COMPLETED